Both Drugs Aim to Treat the Same Problem

Warfarin (Coumadin) is a blood-thinning medication that was developed many years ago to treat atrial fillibration, the same heart condition that Pradaxa (dabigatran etexilate) aims to rectify. Atrial fibrillation increases a person’s risk for having a stroke and/or developing blood clots. Non-vacular atrial fillibration is a form of cardiac arrhythmia, or irregular heartbeat. Atrial fillibration does not always produce physical symptoms in individuals suffering from it. When atrial fillibration does show itself through symptoms, they sometimes can’t be treated because they are idiomatic. Regardless, atrial fibrillation does cause nasty effects in many of its users. The health condition can be identified by acquiring the following symptoms:
• Chest pain
• Congestive heart failure
• High blood pressure
• Fainting
• Heart and/or chest palpitations

Why Create Pradaxa?

Warfarin—a drug that is taken orally, as is Pradaxa—is a largely ineffective drug because it is so difficult to dose and to monitor. Warfarin imposes a large risk of negative drug interactions which in turn restricts the patient’s diet to boost the potentiality of accurate monitoring of the drug’s behavior. All of this is extremely imposing on the patient’s way of life. You could need Pradaxa Injury Lawyers for your case.


The limited nature of Warfarin offered Boehringer Ingelheim the opportunity in 2011 to cash in on making a blood thinning alternative. That is where Pradaxa comes in. Pradaxa is also a direct thrombin inhibitor, and released the atrial fillibration sufferer from the INR monitoring that was and is always necessary about Warfarin prescription. Pradaxa eliminated many side effects and/or risks that were unique to Warfarin.
However, Pradaxa lost its popularity when hundreds died in one year and thousands upon thousands reported a range of very serious injuries and/or health complications to the FDA (U.S. Drug and Food Administration). A study lately published the results of data collected in a controlled group of users of both Pradaxa and Warfarin. It showed that Pradaxa is 5 times more lethal than Warfarin, as users of the former drug often bleed out internally as a result of pH levels that are too high. The famous RE-LY trial revealed that people stopped taking Pradaxa sooner than they did Warfarin because users of the former drug experienced a higher incident of gastrointestinal problems.